Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Barinthus Biotherapeutics's current 3-Year Share Buyback Ratio was -2.70%.
The historical rank and industry rank for Barinthus Biotherapeutics's 3-Year Share Buyback Ratio or its related term are showing as below:
STU:2AB'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -4.3 Med: -2.7 Max: -2.7
Current: -2.7
During the past 7 years, Barinthus Biotherapeutics's highest 3-Year Share Buyback Ratio was -2.70%. The lowest was -4.30%. And the median was -2.70%.
STU:2AB's 3-Year Share Buyback Ratio is ranked better than 74.24% of 1192
companies
in the Biotechnology industry
Industry Median: -11.85
vs STU:2AB: -2.70
Barinthus Biotherapeutics (STU:2AB) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Barinthus Biotherapeutics 3-Year Share Buyback Ratio Related Terms
STU:2AB vs VTGN, PSTV, PVCT: 3-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Barinthus Biotherapeutics's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Barinthus Biotherapeutics 3-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Barinthus Biotherapeutics's 3-Year Share Buyback Ratio falls into.
Barinthus Biotherapeutics 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -2.70 mean?
Barinthus Biotherapeutics (STU:2AB) has a 3-Year Share Buyback Ratio of -2.70 as of Mar. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Barinthus Biotherapeutics and its competitors. According to the industry distribution chart, Barinthus Biotherapeutics ranks #307 out of 1192 companies in the Biotechnology industry, placing it in the top 25.8%.
Is Barinthus Biotherapeutics' 3-Year Share Buyback Ratio too high?
Barinthus Biotherapeutics' current 3-Year Share Buyback Ratio is -2.70. Based on the distribution chart, Barinthus Biotherapeutics ranks #307 out of 1192 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Barinthus Biotherapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Barinthus Biotherapeutics' 3-Year Share Buyback Ratio compare to VTGN and PSTV?
According to the Biotechnology industry distribution chart, Barinthus Biotherapeutics ranks #307 out of 1192 companies for 3-Year Share Buyback Ratio. This puts Barinthus Biotherapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Barinthus Biotherapeutics and its competitors. Barinthus Biotherapeutics's current 3-Year Share Buyback Ratio is -2.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Barinthus Biotherapeutics stock overvalued right now?
Barinthus Biotherapeutics (STU:2AB) has a current 3-Year Share Buyback Ratio of -2.70. The stock's GF Value™ is €0.94, compared to a current price of €0.54 — trading 43.1% below its estimated fair value. The current 3-Year Share Buyback Ratio is -2.70. Barinthus Biotherapeutics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Barinthus Biotherapeutics (STU:2AB), the current 3-Year Share Buyback Ratio is -2.70 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Barinthus Biotherapeutics (STU:2AB) Overvalued in 2026?
Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued.
The current stock price of €0.54 is trading 43.1% below its estimated GF Value™ of €0.94.
Key valuation signals for STU:2AB:
3-Year Share Buyback Ratio: -2.70
GF Value™: €0.94 vs. price of €0.54 (43.1% below fair value)
No single metric tells the full story. See the STU:2AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
14GF Score
Get the complete analysis for STU:2AB
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2AB has been successfully added to your 